Comparative Pharmacology
Head-to-head clinical analysis: ADENOCARD versus ETHMOZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADENOCARD versus ETHMOZINE.
ADENOCARD vs ETHMOZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adenosine is an endogenous purine nucleoside that acts on A1 and A2 adenosine receptors. It slows conduction through the AV node, interrupts reentry pathways, and can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT).
Class Ic antiarrhythmic; blocks cardiac sodium channels, slowing phase 0 depolarization and reducing conduction velocity in atrial and ventricular myocardium.
6 mg IV bolus over 1-2 seconds, followed by 20 mL saline flush; if no conversion to sinus rhythm within 1-2 minutes, give 12 mg IV bolus; may repeat 12 mg once more if needed.
200-300 mg orally every 8 hours; maximum 900 mg/day.
None Documented
None Documented
Terminal half-life is less than 10 seconds; clinically, the effect is very transient due to rapid cellular uptake and metabolism.
3-12 hours (mean ~6 hours); prolonged in hepatic or renal impairment.
Primarily renal excretion of metabolites; adenosine is rapidly metabolized intracellularly to inosine and adenosine monophosphate, with less than 1% excreted unchanged in urine.
Primarily hepatic metabolism; renal excretion of unchanged drug accounts for <1% of a dose; approximately 10-20% excreted in feces via bile.
Category C
Category C
Antiarrhythmic
Antiarrhythmic